Accreditation and Designation User Manual - OECI
Accreditation and Designation User Manual - OECI Accreditation and Designation User Manual - OECI
4.3. Structures 4.3.1. Yes No not applicable 4.3.1.1. Do you have a private partnership with companies related to research and innovation 4.3.1.2. Do you have a Unit of epidemiology? 4.3.1.3. Do you have a biostatistic unit? 4.3.1.4. Do you have a Unit of health economy? 4.3.1.5. Do you have a data management unit/trial bureau? 4.3.1.6. Do you have a local cancer registry? 4.3.2. Number of studies active (that is open to patient accrual) during year x: X 4.3.3. Number of studies activated in year x: Phase I Phase II Phase III Phase IV # X X X X 4.3.4. Number of new investigator initiated local trials (Percentage of new investigator initiated local trials %) 4.3.5. Number of new investigator initiated national trials (Percentage) 4.3.6. Number of new investigator initiated international trials (Percentage) 4.3.7. Number of new clinical trials with external industrial sponsor (Percentage) 4.3.8. Number of new patients in clinical trials (indicator: number of new patients included in clinical trials /Number of new patients in the institute) 4.3.9. Does your cancer centre have research collaboration with other cancer centres Yes No 4.3.9.1. at national level 4.3.9.2. at international level 38 / OECI Accreditation and Designation / Appendix III
4.4. Research budget including basic/clinical/translational 4.4.1. Total research budget cancer centre X 4.4.2. Nr of EU grants Nr of EU grants Public funding Charities/unrestricted Industrial running in year x coordinated in year x grants partnership funding Research funding sources/total X X X X X amounts received (2008) 4.4.3. Number of patents over the last 5 years: 4.4.4. Number of peer-reviewed publications X per year (year x) national 4.4.5. Number of peer-reviewed publications X per year (year x) international 4.4.6. Impactfactor cumulative 4.4.7. Number of publications with X impactfactor > 10 Appendix III / OECI Accreditation and Designation / 39
- Page 44 and 45: 5.8.2 Step 8: activities and respon
- Page 46 and 47: 5.9 Step 9: Formulate improvement p
- Page 48 and 49: 5.10.1 Evaluation of the A&D Progra
- Page 50 and 51: Intermediate self-assessment (optio
- Page 52 and 53: Owner: OECI Organisation of Europea
- Page 54 and 55: Owner: OECI Organisation of Europea
- Page 56 and 57: Owner: OECI Organisation of Europea
- Page 58 and 59: 2 / OECI Accreditation and Designat
- Page 60 and 61: Qualitative Questionnaire 1. Genera
- Page 62 and 63: 1.3.2. Administration of cytostatic
- Page 64 and 65: 1.4.6. Roles and tasks of the membe
- Page 66 and 67: 1.4.12. Registration and evaluation
- Page 68 and 69: 1.5.5. Quality assurance in all are
- Page 70 and 71: 2.4.5. Smoking control in the cance
- Page 72 and 73: 3.4.4. Palliative and terminal care
- Page 74 and 75: 4. Research, innovation and develop
- Page 76 and 77: 4.3. Resources and materials 4.3.1.
- Page 78 and 79: 5. Teaching and continuing educatio
- Page 80 and 81: 6. Patient related 6.4. Process con
- Page 82 and 83: 6.5. Safeguarding the quality syste
- Page 84 and 85: 1.4.7. at national level at regiona
- Page 86 and 87: 2.3. Infrastructures with a focus o
- Page 88 and 89: 2.9. Radiology 2.9.1. Number of CT
- Page 90 and 91: 2.15. Facilities 2.15.1. On site Ac
- Page 92 and 93: 3.4. Human resources (4) 3.4.1. Pat
- Page 96 and 97: 5. Education 5.1. Education 5.1.1.
- Page 98 and 99: Planning of the project Start Expla
- Page 100 and 101: Go to the qualitative and quantitat
- Page 102 and 103: 3. Before moving to the next item p
- Page 104 and 105: The following screen will appear. F
- Page 106 and 107: • Close the questionnaire if you
- Page 108 and 109: Print only the questions or the ful
- Page 110 and 111: Workspace: Go to the questionnaires
- Page 112 and 113: 2. Preparing a peer review Open a q
- Page 114 and 115: To view the remarks and the score o
- Page 116 and 117: 2 / OECI Accreditation and Designat
- Page 118 and 119: Qualitative Questionnaire 1. Genera
- Page 120 and 121: 1.3.2. Administration of cytostatic
- Page 122 and 123: 1.4.6. Roles and tasks of the membe
- Page 124 and 125: 1.4.12. Registration and evaluation
- Page 126 and 127: 1.5.5. Quality assurance in all are
- Page 128 and 129: 2.4.5. Smoking control in the cance
- Page 130 and 131: 3.4.4. Palliative and terminal care
- Page 132 and 133: 4. Research, innovation and develop
- Page 134 and 135: 4.3. Resources and materials 4.3.1.
- Page 136 and 137: 5. Teaching and continuing educatio
- Page 138 and 139: 6. Patient related 6.4. Process con
- Page 140 and 141: 6.5. Safeguarding the quality syste
- Page 142 and 143: 1.4.7. at national level at regiona
4.4. Research budget including basic/clinical/translational<br />
4.4.1. Total research budget cancer centre X<br />
4.4.2.<br />
Nr of EU grants Nr of EU grants Public funding Charities/unrestricted Industrial<br />
running in year x coordinated in year x grants partnership funding<br />
Research funding sources/total X X X X X<br />
amounts received (2008)<br />
4.4.3. Number of patents over the last 5 years:<br />
4.4.4. Number of peer-reviewed publications X<br />
per year (year x) national<br />
4.4.5. Number of peer-reviewed publications X<br />
per year (year x) international<br />
4.4.6. Impactfactor cumulative<br />
4.4.7. Number of publications with X<br />
impactfactor > 10<br />
Appendix III / <strong>OECI</strong> <strong>Accreditation</strong> <strong>and</strong> <strong>Designation</strong> / 39
Change language